Price
Financials
Standalone, Rs crore| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 68.10 | 66.73 | 67.81 | 72.06 | 65.31 | 70.89 | 74.49 | 76.99 | 68.80 |
| Expenses | 54.70 | 52.85 | 52.75 | 53.10 | 50.41 | 56.24 | 59.13 | 62.03 | 54.26 |
| Operating Profit | 13.40 | 13.88 | 15.06 | 18.96 | 14.90 | 14.65 | 15.36 | 14.96 | 14.54 |
| OPM % | 19.68% | 20.80% | 22.21% | 26.31% | 22.81% | 20.67% | 20.62% | 19.43% | 21.13% |
| Other Income | 0.15 | 0.21 | 0.87 | 0.16 | 0.96 | -2.56 | 0.68 | 1.66 | 0.64 |
| Interest | 9.45 | 6.32 | 5.90 | 6.28 | 6.29 | 5.15 | 5.06 | 4.25 | 6.00 |
| Depreciation | 4.60 | 4.60 | 4.51 | 4.69 | 4.64 | 4.66 | 4.67 | 4.75 | 4.69 |
| Profit before tax | -0.50 | 3.17 | 5.52 | 8.15 | 4.93 | 2.28 | 6.31 | 7.62 | 4.49 |
| Tax % | -28.00% | 28.71% | 22.64% | 26.87% | 28.80% | 46.93% | 26.47% | 27.43% | 26.28% |
| Net Profit | -0.36 | 2.26 | 4.28 | 5.96 | 3.51 | 1.21 | 4.63 | 5.53 | 3.31 |
| EPS in Rs | -0.13 | 0.78 | 1.48 | 2.07 | 1.22 | 0.31 | 1.19 | 1.42 | 0.85 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 184 | 171 | 225 | 259 | 280 | 275 | 288 | 291 |
| Expenses | 147 | 133 | 173 | 206 | 223 | 215 | 228 | 232 |
| Operating Profit | 37 | 38 | 52 | 53 | 58 | 60 | 60 | 60 |
| OPM % | 20% | 22% | 23% | 20% | 21% | 22% | 21% | 20% |
| Other Income | 2 | 1 | 76 | 4 | 1 | 1 | 1 | 0 |
| Interest | 38 | 40 | 49 | 35 | 34 | 28 | 21 | 20 |
| Depreciation | 16 | 17 | 17 | 18 | 20 | 18 | 19 | 19 |
| Profit before tax | -15 | -18 | 62 | 3 | 5 | 15 | 21 | 21 |
| Tax % | 25% | 23% | 11% | 179% | 32% | 29% | 30% | |
| Net Profit | -19 | -22 | 55 | -2 | 4 | 10 | 15 | 15 |
| EPS in Rs | -7.03 | -8.14 | 20.54 | -0.79 | 1.35 | 3.64 | 3.83 | 3.77 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 11% | 4% | 7% | ||
| Compounded Profit Growth | % | 22% | 114% | -4% | ||
| Stock Price CAGR | % | % | % | 33% | ||
| Return on Equity | % | 4% | 10% | 10% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 27 | 27 | 27 | 29 | 39 |
| Reserves | 2 | -20 | 36 | 36 | 39 | 68 | 181 |
| Borrowings | 231 | 235 | 226 | 216 | 211 | 204 | 244 |
| Other Liabilities | 127 | 150 | 104 | 96 | 75 | 81 | 93 |
| Total Liabilities | 388 | 392 | 392 | 374 | 352 | 382 | 558 |
| Fixed Assets | 244 | 242 | 240 | 232 | 228 | 217 | 207 |
| CWIP | 0 | 0 | 0 | 9 | 0 | 7 | 82 |
| Investments | 0 | 2 | 3 | 0 | 4 | 8 | 7 |
| Other Assets | 144 | 149 | 149 | 133 | 120 | 150 | 262 |
| Total Assets | 388 | 392 | 392 | 374 | 352 | 382 | 558 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 38 | 31 | 62 | 43 | 58 | 47 | 48 |
| Cash from Investing Activity | -9 | -13 | -6 | -7 | -10 | -24 | -94 |
| Cash from Financing Activity | -37 | -18 | -50 | -42 | -46 | -23 | 126 |
| Net Cash Flow | -8 | -0 | 6 | -6 | 1 | -1 | 81 |
| Free Cash Flow | 27 | 19 | 52 | 36 | 46 | 26 | -32 |
| CFO/OP | 102% | 66% | 119% | 93% | 111% | 84% | 93% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 110 | 73 | 75 | 63 | 67 | 55 |
| Inventory Days | 225 | 422 | 338 | 247 | 309 | 464 | 530 |
| Days Payable | 99 | 186 | 185 | 130 | 129 | 194 | 230 |
| Cash Conversion Cycle | 229 | 345 | 226 | 193 | 243 | 336 | 354 |
| Working Capital Days | 51 | -5 | 28 | 42 | 16 | 26 | 6 |
| ROCE % | 9% | 14% | 13% | 14% | 15% | 12% |
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters | 63.56% | 63.56% | 63.72% | 63.79% |
| FIIs | 1.00% | 1.10% | 0.85% | 0.43% |
| DIIs | 11.34% | 11.24% | 12.88% | 12.92% |
| Public | 24.10% | 24.09% | 22.55% | 22.84% |
| No. of Shareholders | 18,669 | 16,181 | 15,222 | 12,612 |
Fundamentals
Market Cap₹ 728 Cr.
Current Price₹ 187
Stock P/E47.4
Book Value₹ 56.7
ROCE11.6 %
ROE10.3 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)7%
Compounded Profit Growth (TTM)-4%
Standalone figures.
Valuation
Market capRs 511 Cr
Enterprise valueRs 723 Cr
P/E (TTM)34.33x
Price to book8.12x
Price to sales1.78x
EV / EBITDA11.92x
EV / EBIT17.25x
EV / sales2.51x
Price to cash flow12.00x
Earnings yield2.91%
Profitability
Operating margin (excl. other income)20.35%
Operating margin (incl. other income)21.73%
EBITDA margin21.07%
Pre-tax margin7.35%
Net profit margin5.17%
Net margin, latest quarter7.18%
ROE-3.37%
ROCE13.40%
ROA-0.55%
ROE, 3-year average11.62%
ROCE, 3-year average21.38%
ROA, 3-year average2.64%
ROIC (approx.)-12.02%
Tax rate178.81%
Other income / net worth5.68%
Growth
Sales growth (latest year)14.94%
Profit growth (latest year)-103.83%
Sales CAGR, 3 years12.01%
Sales growth QoQ3.36%
Profit growth QoQ19.44%
Sales growth YoY (latest quarter)6.84%
Profit growth YoY (latest quarter)-7.21%
Per share
EPS (TTM)Rs 5.55
EPS (latest year)Rs -0.79
EPS (latest quarter)Rs 2.06
EPS, 3-year averageRs 3.87
Book value per shareRs 23.44
Sales per shareRs 107.23
Cash flow per shareRs 15.87
Free cash flow per shareRs -11.93
Efficiency
Asset turnover0.69x
Fixed asset turnover1.12x
Inventory turnover2.35x
Inventory days155 days
Debtor days75 days
Debtors turnover4.84x
Creditor days230 days
Cash conversion cycle354 days
Working capital days6 days
Leverage
Total debtRs 216 Cr
Cash and bankRs 4 Cr
Net debtRs 212 Cr
Debt to equity3.43x
Net debt / EBITDA3.49x
Interest coverage2.02x
Owners' fund to total sources16.81%
Debt to assets57.65%
Cash flow
Cash from Operating Activity (latest year)Rs 43 Cr
Cash from Investing Activity (latest year)Rs -7 Cr
Cash from Financing Activity (latest year)Rs -42 Cr
Net Cash Flow (latest year)Rs -6 Cr
Free cash flow (latest year)Rs -32 Cr
FCFE (approx.: FCF + change in debt)Rs -42 Cr
Cash from ops / profit, 5 years3.15x
Sales to cash flow6.09x
Statement figures
Net sales (TTM)Rs 288 Cr
Net sales (latest year)Rs 259 Cr
Sales (latest quarter)Rs 77 Cr
Operating profit excl. other income (latest year)Rs 53 Cr
Operating profit (latest quarter)Rs 15 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs 61 Cr
PBDT (TTM)Rs 40 Cr
Profit before tax (TTM)Rs 21 Cr
Tax (latest year)Rs 5 Cr
Net profit (TTM)Rs 15 Cr
Net profit (latest year)Rs -2 Cr
Net profit (latest quarter)Rs 6 Cr
Depreciation (TTM)Rs 19 Cr
Depreciation (latest quarter)Rs 5 Cr
Interest (TTM)Rs 21 Cr
Cost of goods sold (latest year)Rs 162 Cr
Total expenditure (latest year)Rs 206 Cr
Total income (latest year)Rs 263 Cr
Share capitalRs 27 Cr
ReservesRs 36 Cr
Shareholders' fundsRs 63 Cr
Total assetsRs 374 Cr
Net blockRs 232 Cr
Capital work in progressRs 9 Cr
ReceivablesRs 54 Cr
InventoryRs 69 Cr
Other liabilitiesRs 96 Cr
Shares outstanding (crore)2.68
Ownership
Promoter holding63.79%
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | AMANTA | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +0.6% | -2.8% | +3.4 pts |
| 1 month | +0.2% | -6.8% | +7.0 pts |
| 3 months | +16.7% | -7.6% | +24.4 pts |
| 6 months | +90.8% | +0.4% | +90.4 pts |
| 1 year | +36.8% | -9.9% | +46.7 pts |
1 mutual fund schemes hold about ₹38 Cr.
Over three months 0 bought more and 0 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Bandhan Small Cap Fund | 0.11% | 38 |
Red flags
F-score 4 of 8| look | Profit leans on other income Other income was 133% of pre-tax profit in 2026 |
| look | On NSE surveillance On NSE surveillance: ESM |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹69 Cr +5.3% vs Jun 2025.
Net profit ₹3 Cr -5.7%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
| Date | Type | What it says |
|---|---|---|
| 2026-10-01 | Updates | Submission of Disclosures under Regulation 7(2) of the SEBI (Prohibition of InsiderTrading) Regulations, 2015. |
| 2026-09-30 | Updates | Submission of Disclosures under Regulation 7(2) of the SEBI (Prohibition of InsiderTrading) Regulations, 2015.. |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
ESM: stage 1